Introduction and Statement of Policy Sample Clauses

Introduction and Statement of Policy. The National Institutes of Health (NIH) has established NIH-designated data repositories (e.g., database of Genotypes and Phenotypes (dbGaP), Sequence Read Archive (SRA), NIH Established Trusted Partnerships) for securely storing and sharing controlled-access human data submitted to NIH under the NIH Genomic Data Sharing (GDS)
Sample 1Sample 2Sample 3See All (305)
AutoNDA by SimpleDocs
Introduction and Statement of Policy. The National Institutes of Health (NIH) has established NIH-designated data repositories (e.g., database of Genotypes and Phenotypes (dbGaP), Sequence Read Archive (SRA), NIH Established Trusted Partnerships) for securely storing and sharing controlled-access human data submitted to NIH under the NIH Genomic Data Sharing (GDS) Policy. Because the volume of human genomic and phenotypic data contained in these repositories is substantial and, in some instances, potentially sensitive (e.g., data related to the presence or risk of developing particular diseases or conditions and information regarding family relationships or ancestry), data must be shared in a manner consistent with the research participants’ informed consent, and the confidentiality of the data and the privacy of participants must be protected. Access to human genomic data will be provided to research investigators who, along with their institutions, have certified their agreement with the expectations and terms of access detailed below. It is the intent of NIH and the NCI that approved users of controlled-access datasets obtained through this DAR recognize any restrictions on data use established by the submitting institution through the Institutional Certification and stated on the dbGaP study page. Definitions of terminology used in this document are found in the Appendix. The parties to this agreement include: the Principal Investigator (PI) requesting access to the genomic study dataset (an “Approved User”), the PI’s home institution as represented by the Institutional Signing Official designated through the eRA Commons system (the “Requester”), and the relevant NIH Institute or Center (IC). The effective date of this agreement shall be the Project Approval Date, as specified on the Data Access Committee (DAC) approval notification.
Sample 1Sample 2Sample 3See All (9)
Introduction and Statement of Policy. The National Institutes of Health (NIH) has developed central data repositories to archive and distribute the results of studies provided by Contributing Investigators examining the relationship between genomic data (e.g., genotype, sequence, or epigenetic information) and phenotype. Such studies include genome-wide association studies, medical sequencing, and molecular diagnostic assays. Implicit in the establishment of the NIH data repositories, for example the database of Genotypes and Phenotypes (dbGaP), is the view that scientific progress in this area will be greatly enhanced if the data produced by these studies are readily available to all investigators in the research community. Dataset access will be provided to research investigators who, along with their institutions, have certified their agreement with the expectations and terms of access detailed below. It is the intent of the NIH and National Institute on Aging (NIA) that Approved Users of NIH-provided datasets recognize any restrictions on data use delineated within the original informed consent agreements of contributing studies, as identified by the submitting institutions and stated on database websites. Definitions of terminology used in this document are found in the Appendix. The parties to this agreement include: the Principal Investigator (PI) requesting access to the genomic study dataset (“the Approved User”), his/her home institution as represented by the Institutional Signing Official designated through the eRA Commons system (“the Requester”), and the NIA, NIH. The effective date of this agreement shall be the Project Approval Date, as specified on the Data Access Committee approval notification.
Sample 1
Introduction and Statement of Policy. The National Institutes of Health (NIH) has established the Rapid Acceleration of Diagnostics (RADxSM) Data Hub for securely storing and sharing human data submitted to NIH as part of the RADxSM program. Because the volume of human data maintained in this data repository is substantial and potentially sensitive (e.g., data related to the presence or risk of developing particular diseases or conditions and information regarding family relationships or ancestry), data must be shared in a manner consistent with the research participants’ informed consent, and the confidentiality of the data and the privacy of participants must be protected. Access to RADxSM data will be provided to research investigators who, along with their institutions, have certified their agreement with the expectations and terms of access detailed below. NIH expects that, through Data Access Request (DAR) process, approved users of open and controlled-access datasets recognize any restrictions on data use established by the Submitting Institutions through the Institutional Certification. Definitions of the underlined terminology in this document are found in section 13. The parties to this Agreement include: the Principal Investigator (PI) requesting access to the genomic study dataset (an “Approved User”), the PI’s home institution (the “Requester”) as represented by the Institutional Signing Official designated through the eRA Commons system, and the NIH. The effective date of this Agreement shall be the DAR Approval Date, as specified in the notification of approval of the Data Access Committee (DAC).
Sample 1
Introduction and Statement of Policy. The Women’s Interagency HIV Study (WIHS), funded by the National Institutes of Health (NIH), has an established central host genomic data repository called the WIHS Genomics Database for securely storing and sharing human host genomic data submitted to the WIHS. Implicit in the establishment of the WIHS Genomics Database is that scientific progress in genomic research will be greatly enhanced if the data are readily available to all approved scientific investigators and shared in a manner consistent with the research participants’ informed consent. Access to human genomic data will be provided to research investigators who, along with their WIHS Contact (e.g., site PI), have certified their agreement with the expectations and terms of access detailed below. It is the intent of NIH and the WIHS that approved users of the WIHS Genomics Database datasets recognize any restrictions on data use established by the WIHS stated on the WIHS Concept Sheet, the WIHS Genomic Data Code of Conduct, and the WIHS Genomic Data Use Contract. Definitions of terminology used in this document are found in Appendix 1. This Data Use Agreement (the “Agreement”) is by and between the WIHS Principal Investigators [Drs. Xxxx Xxxxxxxx and Xxxx Xxxxxxx (Xxxxx University); and Dr. Xxxx Xxxxx (Georgetown University); and Drs. Xxxxxxx Xxxxx and Xxxxxxxxx Xxxxx (Xxxxx Xxxxxxx University); and Xx. Xxxxxxx Xxxxxxx (Montefiore Medical Center); and Drs. Xxxxxx Xxxxx and Xxxxxx Xxxxxx (Chicago WIHS Consortium : Cook County Hospital, University of Illinois at Chicago, Rush-Presbyterian-St. Luke's Medical Center, and Northwestern Memorial Hospital); and Drs. Xxxxxxx Xxxx and Xxxxxx Xxxxxxx Xxxxx (The University of Alabama at Birmingham); and Drs. Xxxx Xxxxxxxxxx, Xxxxxxx Xxxx and Xxxxxxx Xxxxxxxxx (The University of California at San Francisco); and Drs. Xxxxxxxx Xxxxxx and Xxxx Xxxxxx (The University of Miami); and Xx. Xxxxxxx Xxxxxx- Parker (The University of Mississippi at Xxxxxxx); and Xx. Xxx Xxxxxxx (The University of North Carolina at Chapel Hill); and Drs. Xxxxxx Xxxxxxx and Xxxxxxx Xxxxxxxxx (The State University of New York at Brooklyn), (hereinafter referred to individually as “WIHS CONSORTIUM”) and [INSERT INVESTIGATOR NAME] (“Approved User”). This agreement (“Agreement”) establishes the terms and conditions under which the User will obtain and use certain data (“Genomics Dataset”) from the Women’s Interagency HIV Study (WIHS) maintained by the WIHS Consortium. The effective date of ...
Sample 1

Related to Introduction and Statement of Policy

  • Statement of Policy In accordance with the Federal Family and Medical Leave Act (FMLA) and the California Family Rights Act (CFRA), the City will provide family and medical care leave and military family leave for eligible employees, as defined.

  • Form of Policies The minimum limits of policies of insurance required of Tenant under this Lease shall in no event limit the liability of Tenant under this Lease. Such insurance shall (i) be issued by an insurance company having an AM Best rating of not less than A‑X (or to the extent AM Best ratings are no longer available, then a similar rating from another comparable rating agency), or which is otherwise acceptable to Landlord and licensed to do business in the State of California, (ii) be in form and content reasonably acceptable to Landlord and complying with the requirements of Section 10.3 (including, Sections 10.3.1 through 10.3.5), (iii) Tenant shall not do or permit to be done anything which invalidates the required insurance policies, and (iv) provide that said insurance shall not be canceled or coverage changed unless thirty (30) days' prior written notice shall have been given to Landlord and any mortgagee of Landlord, the identity of whom has been provided to Tenant in writing. Tenant shall deliver said policy or policies or certificates thereof and applicable endorsements which meet the requirements of this Article 10 to Landlord on or before (I) the earlier to occur of: (x) the Lease Commencement Date, and (y) the date Tenant and/or its employees, contractors and/or agents first enter the Premises for occupancy, construction of improvements, alterations, or any other move-in activities, and (II) five (5) business days after the renewal of such policies. In the event Tenant shall fail to procure such insurance, or to deliver such policies or certificates and applicable endorsements, Landlord may, at its option, after written notice to Tenant and Tenant's failure to obtain such insurance within five (5) days thereafter, procure such policies for the account of Tenant and the sole benefit of Landlord, and the cost thereof shall be paid to Landlord after delivery to Tenant of bills therefor.

  • Application of Policy The policy is to apply to everyone on site without distinction.

  • Dissemination of Policy All members of the contractor's staff who are authorized to hire, supervise, promote, and discharge employees, or who recommend such action, or who are substantially involved in such action, will be made fully cognizant of, and will implement, the contractor's EEO policy and contractual responsibilities to provide EEO in each grade and classification of employment. To ensure that the above agreement will be met, the following actions will be taken as a minimum: a. Periodic meetings of supervisory and personnel office employees will be conducted before the start of work and then not less often than once every six months, at which time the contractor's EEO policy and its implementation will be reviewed and explained. The meetings will be conducted by the EEO Officer. b. All new supervisory or personnel office employees will be given a thorough indoctrination by the EEO Officer, covering all major aspects of the contractor's EEO obligations within thirty days following their reporting for duty with the contractor. c. All personnel who are engaged in direct recruitment for the project will be instructed by the EEO Officer in the contractor's procedures for locating and hiring minorities and women. d. Notices and posters setting forth the contractor's EEO policy will be placed in areas readily accessible to employees, applicants for employment and potential employees. e. The contractor's EEO policy and the procedures to implement such policy will be brought to the attention of employees by means of meetings, employee handbooks, or other appropriate means.

  • Summary of Policy and Prohibitions on Procurement Lobbying Pursuant to State Finance Law §139-j and §139-k, this Contract includes and imposes certain restrictions on communications between OGS and a Vendor during the procurement process. A Vendor is restricted from making contacts from the earliest notice of intent to solicit offers/bids through final award and approval of the Procurement Contract by OGS and, if applicable, the Office of the State Comptroller (“restricted period”) to other than designated staff unless it is a contact that is included among certain statutory exceptions set forth in State Finance Law §139-j(3)(a). Designated staff, as of the date hereof, is identified in Appendix G, Contractor and OGS Information, or as otherwise indicated by OGS. OGS employees are also required to obtain certain information when contacted during the restricted period and make a determination of the responsibility of the Vendor pursuant to these two statutes. Certain findings of non-responsibility can result in rejection for contract award and in the event of two findings within a four-year period; the Vendor is debarred from obtaining governmental Procurement Contracts. Further information about these requirements can be found on the OGS website: xxxx://xxx.xxx.xx.xxx/aboutOgs/regulations/defaultSFL_139j-k.asp.

  • Confirmation and Statements Promptly after the close of business on each day, the Custodian shall furnish the Fund with confirmations and a summary of all transfers to or from the account of the Fund during the day. Where securities purchased by the Fund are in a fungible bulk of securities registered in the name of the Custodian (or its nominee) or shown in the Custodian's account on the books of a Securities Depository, the Custodian shall by book-entry or otherwise identify the quantity of those securities belonging to the Fund. At least monthly, the Custodian shall furnish the Fund with a detailed statement of the Securities and monies held for the Fund under this Agreement.

  • STATEMENT OF PHILOSOPHY The University of Minnesota and the Union are committed to recognizing and acknowledging the healthy and positive diversity that we have on the University campuses. Further, the parties recognize that all employees have the right to work in a productive environment in which there is no verbal or physical intimidation, or discrimination or harassment based on the criteria provided in Section 1, Discrimination Prohibition, and Section 2, Sexual Harassment. It is in this spirit that the parties agree to the provisions of this Article. This statement shall not be grievable nor shall either party use this Section as evidence or argument in arbitration.

  • Compliance with Consensus Policies and Temporary Policies Registry Operator shall comply with and implement all Consensus Policies and Temporary Policies found at <xxxx://xxx.xxxxx.xxx/general/consensus-­‐policies.htm>, as of the Effective Date and as may in the future be developed and adopted in accordance with the ICANN Bylaws, provided such future Consensus Polices and Temporary Policies are adopted in accordance with the procedure and relate to those topics and subject to those limitations set forth in Specification 1 attached hereto (“Specification 1”).

  • Litigation and Compliance ‌ (a) Except as disclosed in the Disclosure Letter, to the best of GLC’s knowledge, there are no actions, suits, claims or proceedings, whether in equity or at law or, any Governmental investigations pending or threatened: (i) against or affecting GLC or the GLC Subsidiaries or with respect to or affecting any asset or property owned, leased or used by GLC or the GLC Subsidiaries; or (ii) which question or challenge the validity of this Agreement, or the Amalgamation or any action taken or to be taken pursuant to this Agreement, or the Amalgamation; nor is GLC aware of any basis for any such action, suit, claim, proceeding or investigation. (b) There is not outstanding against GLC or the GLC Subsidiaries, any judgment, decree, injunction, rule, order or award of any court, Governmental entity, commission, board, bureau, agency, or arbitrator. (c) Each of GLC and the GLC Subsidiaries has conducted and is conducting its business in compliance with, and is not in default or violation under, and has not received notice asserting the existence of any default or violation under, any Law applicable to its business or operations, except for non-compliance, defaults and violations which would not, in the aggregate, have a Material Adverse Effect on GLC. (d) Neither GLC nor any of its assets, including the GLC Subsidiaries, is subject to any judgment, order or decree entered in any lawsuit or proceeding which has had, or which is reasonably likely to have, a Material Adverse Effect on GLC or which is reasonably likely to prevent GLC from performing its obligations under this Agreement. (e) To the best knowledge of GLC, each of GLC and the GLC Subsidiaries has duly filed or made all reports and returns required to be filed by it with any Government and has obtained all permits, licenses, consents, approvals, certificates, registrations and authorizations (whether Governmental, regulatory or otherwise) which are required in connection with its business and operations, except where the failure to do so has not had and will not have a Material Adverse Effect on GLC.

  • Project Monitoring Reporting and Evaluation The Recipient shall furnish to the Association each Project Report not later than forty-five (45) days after the end of each calendar semester, covering the calendar semester.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!